REGULATION OF PROSTAGLANDIN-D(2)-RECEPTOR AND PROSTAGLANDIN-E(2)-RECEPTOR BINDING IN THE CENTRAL-NERVOUS-SYSTEM

被引:0
作者
MORII, H
WATANABE, Y
机构
[1] OSAKA BIOSCI INST,DEPT NEUROSCI,6-2-4 FURUEDAI,OSAKA 565,JAPAN
[2] RES DEV CORP JAPAN,PRECURSOR RES EMBRYON SCI & TECHNOL,CELL & INFORMAT,OSAKA,JAPAN
来源
JOURNAL OF LIPID MEDIATORS | 1993年 / 6卷 / 1-3期
关键词
PROSTAGLANDIN; BRAIN; PROTEIN PHOSPHORYLATION; GLYCOCONJUGATE; GLYCOLIPID;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostaglandin (PG) D2 and PGE2 receptor binding activities are regulated in various fashions. The protein phosphorylation by exogenous cAMP-dependent protein kinase or calmodulin-dependent protein kinase II significantly increased PGE2 binding activity through an increase in the apparent amount of the maximal binding, suggesting that the PGE2 receptor may be regulated through protein phosphorylation-dephosphorylation. Other possible regulatory mechanisms were found as the result of studies on functional modification of glycoconjugates. Pretreatment with glycoprotein-specific endoglycosidases (peptide N-glycohydrolase F, endo-alpha-N-acetylgalactosaminidase) decreased both PGD2 and PGE2 receptor binding activities and consequently these activities became nonspecific ones. In addition, these binding activities were increased by the addition of a ganglioside or cerebroside mixture, but not ceramide. The addition of separate purified glycolipids showed more specifically their effect on each PG binding. PGD2 binding activity was increased by GD1a and GQ1b and decreased by GM1 and GT1a, while PGE2 binding activity was increased by GQ1b and galactocerebroside. In such a way, PG receptors may require some specific microenvironment for their maximal binding activity.
引用
收藏
页码:445 / 451
页数:7
相关论文
共 50 条
[21]   ATRIAL-NATRIURETIC-FACTOR RECEPTOR SUBTYPES IN THE RAT CENTRAL-NERVOUS-SYSTEM [J].
KONRAD, EM ;
THIBAULT, G ;
SCHIFFRIN, EL ;
CANTIN, M .
HYPERTENSION, 1991, 17 (06) :1144-1151
[22]   Development of prostaglandin D2 receptor antagonist:: discovery of highly potent antagonists [J].
Torisu, K ;
Kobayashi, K ;
Iwahashi, M ;
Nakai, Y ;
Onoda, T ;
Nagase, T ;
Sugimoto, I ;
Okada, Y ;
Matsumoto, R ;
Nanbu, F ;
Ohuchida, S ;
Nakai, H ;
Toda, M .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (17) :4685-4700
[23]   Discovery of selective indole-based prostaglandin D2 receptor antagonist [J].
Iwahashi, Maki ;
Shimabukuro, Atsushi ;
Onoda, Takahiro ;
Matsunaga, Yoko ;
Okada, Yutaka ;
Matsumoto, Ryoji ;
Nambu, Fumio ;
Nakai, Hisao ;
Toda, Masaaki .
BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (15) :4574-4588
[24]   Development of a prostaglandin D2 receptor antagonist:: discovery of a new chemical lead [J].
Torisu, K ;
Kobayashi, K ;
Iwahashi, M ;
Egashira, H ;
Nakai, Y ;
Okada, Y ;
Nanbu, F ;
Ohuchida, S ;
Nakai, H ;
Toda, M .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2005, 40 (05) :505-519
[25]   MODULATION OF INTEGRIN-LAMININ RECEPTOR FUNCTION ON MAMMARY-TUMOR CELLS BY PROSTAGLANDIN E(2) RECEPTOR ANTAGONISM [J].
ZHANG, SZ ;
FULTON, AM .
CANCER LETTERS, 1994, 85 (02) :233-238
[26]   Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus [J].
Nagib, Marwa M. ;
Yu, Ying ;
Jiang, Jianxiong .
PHARMACOLOGY & THERAPEUTICS, 2020, 209
[27]   Identification of a prostaglandin E2 receptor splice variant and its expression in rat tissues [J].
Oldfield, S ;
Grubb, BD ;
Donaldson, LF .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2001, 63 (04) :165-173
[28]   EP1 receptor is involved in prostaglandin E2-induced osteosarcoma growth [J].
Niu, Jing-cai ;
Ma, Nan ;
Liu, Wei ;
Wang, Pei-ji .
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2019, 19 (03) :265-273
[29]   EFFECT OF METHOTREXATE ON THE RELEASE OF PROSTAGLANDIN-E2, PROSTAGLANDIN-D2, AND PROSTAGLANDIN-I2 FROM SMALL-INTESTINE IN THE RAT INVIVO [J].
WEILER, H ;
MOSER, U ;
GEROK, W .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1990, 116 (06) :629-632
[30]   Distinct Roles of Central and Peripheral Prostaglandin E2 and EP Subtypes in Blood Pressure Regulation [J].
Yang, Tianxin ;
Du, Yaomin .
AMERICAN JOURNAL OF HYPERTENSION, 2012, 25 (10) :1042-1049